latest news releases from the newsroom
True North Gems
True North Gems Acquires Baffin Island Sapphire Discovery
VANCOUVER, British Columbia, Nov. 20, 2003 (PRIMEZONE) -- True North Gems (Other OTC:TNGMF) (TSX Venture Exchange:TGX) has optioned 100 percent interest in two Baffin Island properties with confirmed sapphire mineralization of exceptional blue colour. The property package encompasses 1,004 hectares (2,482 acres) and this acquisition is a significant step toward True North Gems objective of becoming North America's premier coloured gemstone company.
Calypso Wireless, Inc.
Calypso Wireless' Technology to Revolutionize Cable Companies' Revenue Model
MIAMI LAKES, Fla., Nov. 20, 2003 (PRIMEZONE) -- Calypso Wireless, Inc. (Pink Sheets:CLYW), announced today that the company is in negotiations with one of the largest cable companies in the U.S. to license and purchase Calypso's ASNAP(tm) technology and related products to the cable company. Calypso Wireless has proprietary technology that seamlessly switches back and forth between cellular (GSM/GPRS or CDMA) networks and Wi-Fi wireless local area networks (WLAN) utilizing the 802.11 standard without losing connectivity. This makes Calypso's technology a natural fit for cable companies such as Comcast (Nasdaq:CMCSA), Charter Communications (Nasdaq:CHTR) and Cablevision (NYSE:CVC).
Pharmexa announces promising preliminary data from a clinical trial with the HER-2 Protein AutoVac breast cancer vaccine
HORSHOLM, Denmark, Nov. 20, 2003 (PRIMEZONE) -- Pharmexa -- Summary: The preliminary data from a phase I trial with the HER-2 Protein AutoVac(TM) vaccine in 10 breast cancer patients in the US indicate that the vaccine is safe and induces antibodies. Pharmexa continues the planning of the further development of the vaccine. Final data from the trial is expected in the beginning of 2004. The company expects to seek additional financing from existing shareholders and new investors through a new share issue in Q1 2004.Promising preliminary data from the HER-2 Protein AutoVac(TM) trial in the USA Pharmexa has now received preliminary antibody results from the patients in the clinical phase I trial with the HER-2 Protein AutoVac(TM) vaccine that is currently conducted in the US. The results, which are based on analysis following 3 of a total of 4 scheduled immunizations of 10 patients shows immune responses in 5 of the patients. So far, no vaccine related serious adverse events have been reported.
Brinova Fastigheter AB Listed at Stockholmsborsen
STOCKHOLM, Sweden, Nov. 20, 2003 (PRIMEZONE) -- Today Brinova Fastigheter AB is listed at Stockholmsborsen. Brinova Fastigheter's shares will be listed on the O-list, after Boss Media AB. "We greet Brinova Fastigheter welcome to Stockholmsborsen," says Kerstin Hessius, president at Stockholmsborsen and deputy head of HEX Integrated Markets. Brinova is a real estate company. The company owns and administers about 70 properties mainly located in the south and middle of Sweden. Pictures from the listing ceremony and a web casted interview with Mats Leifland, President and Chief Executive Officer, will be available at www.stockholmsborsen.se, Changes and News/Listings.
Metro Launches Real Estate Newspaper in Stockholm
BERTRANGE, Luxembourg, Nov. 20, 2003 (PRIMEZONE) -- Metro International S.A. ("Metro"), the international newspaper group, today announced the launch of a new Real Estate newspaper in Stockholm. 'Metro Hus & Hem' will be delivered by mail each Friday to 875,000 homes in the Stockholm area and thereby become Sweden's largest real estate newspaper.